Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 1313 publications.

Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24

Kawai A, Fuller CC, Koram N, Agan A, Brown J, Burk J, Cai B, Daniels K, Fearrington J, Franklin JM, Hague C, Jamal-allial A, Johannes CB, Kempner M, Layton JB, Ma Q, Mai X, Mayer SE, Pawloski PA, Reynolds JS, Seals RM, Selvan M, Smith S, McMahill-Walraven CN, Gilsenan A, Platt R. Monitoring results from a postapproval safety study of Pfizer-BioNTech COVID-19 vaccine in the United States: vaccine utilization and incidence rates of myocarditis/pericarditis. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):182. doi: 10.1002/pds.5687

Tormos A, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia Esteban R, Plana E, Farsani SF, Perez-Gutthann S, Pladevall-Vila M, Rebordosa C. Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D). Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687

Roberto G, Thurin N, Riera-Arnau J, Paoletti O, Souverein P, Pajouheshnia R, Gini R. Conceptual bases for the standardization of calculation approaches for establishing exposure duration of single drug utilization records in multi-database studies. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):343. doi: 10.1002/pds.5687

Mayer SE, Fuller CC, Haynes K, Alam S, Brown JS, Daniels K, Hawrusik R, Horgan C, Jamal-allial A, Johannes CB, Kawai AT, Layton JB, Mai X, Marshall J, McMahill-Walraven CN, Reynolds JS, Seals R, Selvan M, Stemkowski S, Wang FT, Yost E, Gilsenan A, Platt R. Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):186. doi: 10.1002/pds.5687

Yefimenko N, Weinrib R, Boric K, Riefolo F, Jansen M, Weibel D. The challenges and lessons learnt from conducting COVID-19 monitoring studies through VAC4EU: coordination and management perspective. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):179. doi: 10.1002/pds.5687

Weibel D, De Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A. Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687

Saltus C, Djibo DA, Peetluk L, Kaye J, McMahill-Walraven C, Johannes C, Bernick B, Calingaert B, Franklin J, Graham S, Pigoga J, Shuminski P, Margulis AV. Use of very low-dose vaginal estrogens among postmenopausal women in the US. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):352-3. doi: 10.1002/pds.5687

Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687

Levesque L, Johannes CB, Lecciones JA, Giamberardino H, Marcelon L, Cohen C, Rojas A, Bennett L, Khromava A. Post-authorization safety study: cohort event monitoring for CYD-TDV dengue vaccine (DNG15). Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):592. doi: 10.1002/pds.5687

Ahmadizar F, Fortuny J, Cid-Royo A, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687

Jacobson MH, Krumme A, Gifkins D, Margulis A, Weaver J, Davis KJ. Review of mother-infant linkage algorithms in health care databases. Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):521. doi: 10.1002/pds.5687

Oberprieler NG, Pladevall-Vila M, Johannes CB, Layton JB, Golozar A, Lavallee M, Kubin M, Vizcaya D. FOUNTAIN: a modular research platform for integrated real-world evidence generation. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):243. doi: 10.1002/pds.5687

Abtahi S, Pajouheshnia R, Duran C, Riera-Arnau J, Sturkenboom M, Klungel O. Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of valproates. Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):104. Previously presented at the 21st ISoP Annual Meeting. doi: 10.1002/pds.5687

Singer D, Dubois de Gennes C, Brabant Y, Aris E, Molnar D, Candrilli S, La E. Clinical and economic burden of hospitalized respiratory syncytial virus cases among adults aged 50 years and older with chronic conditions. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S86-7. doi: 10.18553/jmcp.2023.29.10-a.s1

Zhang K, Shah C, Graham C, McBayne T, Schultz B. A cost model comparing long-term prophylaxis options for hereditary angioedema: lanadelumab and berotralsta. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S39. doi: 10.18553/jmcp.2023.29.10-a.s1

Shapouri S, Candrilli S, Miles L, Simpson A, Guittari C. Real-world evidence for risdiplam-treated adults with spinal muscular atrophy: a multicenter study. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S130. doi: 10.18553/jmcp.2023.29.10-a.s1

Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Long-term impact of the gene therapy etranacogene dezaparvovec for the treatment of hemophilia B in the United States. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S36-7.

Pluard T, Sandin R, Parikh R, Ward M, Stansfield L, Nham T, Esterberg L, Cha-Silva A, Shah B. Health care resource utilization and cost comparison among palbociclib, abemaciclib, and ribociclib in US patients with HR+/HER2− metastatic breast cancer. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S17-8. doi: 10.18553/jmcp.2023.29.10-a.s1

Fan Q, Hawe E, Yang J, Burgess B, Bullano M, Mokdad A. Cost outcomes of noninhibitor patients with hemophilia A switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies in the United States. Poster presented at the AMCP Nexus 2023; October 16, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S35.

Charabaty A, Gibble TH, Moses R, Sweeney C, Wolin D, McSorley D, Wang J, Rodriguez M, Park B, Dubinsky M. Assessing bowel urgency in clinical practice: results from a healthcare professional survey. Poster presented at the AJG 2023 Annual Scientific Meeting; October 24, 2023. Vancouver, Canada. [abstract] Am J Gastroenterol. 2023 Oct; 118(10S):S894-5. doi: 10.14309/01.ajg.0000954312.41350.0a

La EM, Bunniran S, Garbinsky D, Reynolds M, Poston S, Harrington L. Knowledge, attitudes, and perceptions of respiratory syncytial virus (RSV) among U.S. adults with diabetes. Poster presented at the ADA 2023 Conference; June 24, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(Suppl 1). doi: 10.2337/db23-524-P

Aris E, Brabant Y, La E, Candrilli S, Molnar D. Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S124. doi: 10.1016/j.jval.2023.03.657

Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA. A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S45. doi: 10.1016/j.jval.2023.03.2298

Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405

Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S115-6. doi: 10.1016/j.jval.2023.03.611

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S187. doi: 10.1016/j.jval.2023.03.1013

Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927

Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378

Poulos C, Mansfield C, Bussberg CJ, Hicks JC, Downey C. Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S359. doi: 10.1016/j.jval.2023.03.2791

Poulos C, Pierce A, Chintakayala PK. A review of the influence of stakeholder preference research on the EtR framework. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S347. doi: 10.1016/j.jval.2023.03.2370

Edwards T, Norcross L, Fine J, Martin S, Coulouvrat C, Spears P, Herold CI, Ferrari G, Onwudiwe N. Side effects and impacts of extended adjuvant endocrine therapy: a qualitative study among women with HR+/HER2- breast cancer. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023 Jun; 41(Suppl 16):e12509. doi: 10.1200/JCO.2023.41.16_suppl.e12509

Houghton K, Hitchens A, Ciepielewska M. Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S155. doi: 10.1016/j.jval.2023.03.2501

Janssen E, Smith I, Liu X, Mansfield C, Pierce A, Huang Q, Kalsekar I. Patient preferences for lung cancer interception therapy. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S343. doi: 10.1016/j.jval.2023.03.1943

Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S180. doi: 10.1016/j.jval.2023.03.972

Mordin M, Castro C, Gnanasakthy A. Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S325. doi: 10.1016/j.jval.2023.03.1852

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503

Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S66-7. doi: 10.1016/j.jval.2023.03.347

McMichael A, Poulos C, Vass C, Boeri M. A literature review assessing the most common attributes used in stated-preference studies assessing influenza vaccination: do we know what health care professionals value? Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S329-30. doi: 10.1016/j.jval.2023.03.1876

Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S120. doi: 10.1016/j.jval.2023.03.632

Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L. Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. Poster presented at the ISPOR 2023 Conference; May 6, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S15. doi: 10.1016/j.jval.2023.03.085

Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Burden of surgery in desmoid tumors. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S22. doi: 10.1016/j.jval.2023.03.117

Gohil S, Johnson ML, Goyal R. Impact of a cancer diagnosis on non-cancer chronic disease medication adherence - a systematic literature review. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S197. doi: 10.1016/j.jval.2023.03.1064

Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W. Insights from social media posts on the lived experience of alzheimer's disease. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S352. doi: 10.1016/j.jval.2023.03.2395

Korgaonkar S, Prajapati P, Barnard M, Goswami S. Evaluation of the association between self-perceptions of aging and care deferrals among US adults aged 50 years or older during the COVID-19 pandemic. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S338. doi: 10.1016/j.jval.2023.03.1920

Johnson ML, Yande S, Aparasu RR, Wanat M, Toale K. Prevalence and factors associated with the use of direct oral anticoagulants and low molecular weight heparins (LMWH) in cancer patients. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S377-8. doi: 10.1016/j.jval.2023.03.2121

Kosa K, Mutebi A, Wang A, Blaedel J, Sacchi M, Martin S. Improvements in symptoms, impact of treatment, and satisfaction with treatment among patients with relapsed or refractory b-cell non-hodgkin lymphoma treated with subcutaneous epcoritamab. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S315. doi: 10.1016/j.jval.2023.03.1800

Maeda-Chubachi T, McLeod L, Cartwright M. Meaningful change in children's dermatology life quality index (DLQI) and lesion counts in patients with molluscum contagiosum. Poster presented at the First International Societies for Investigative Dermatology (ISID2023) Meeting; May 10, 2023. Tokyo, Japan. [abstract] J Invest Dermatol. 2023 May; 143(5 Suppl):S105. doi: 10.1016/j.jid.2023.03.622

Davenport E, Zhou X, Wang J, Nunna S, Oberdhan D, Fernandes A, Mekahli D. Disease burden and disease progression of young adult patients with autosomal dominant polycystic kidney disease. Poster presented at the National Kidney Foundation 2023 Spring Clinical Meeting; April 11, 2023. Austin, TX. [abstract] Am J Kidney Dis. 2023 Apr 1; 81(4, Supple 1):S102. doi: 10.1053/j.ajkd.2023.01.349

Chinthammit C, Mody R, Aguado J, Meyers J. Does weight loss in addition to HbA1c reduction impact health care costs in patients treated with T2D? a retrospective database analysis. Poster presented at the AMCP 2023 Annual Meeting; March 21, 2023. San Antonio, TX. [abstract] J Manag Care Pharm. 2023 Mar; 29(10-2):S27.